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Abstract: Infantile spasms are an epilepsy syndrome with distinctive features, including age 
onset during infancy, characteristic epileptic spasms, and specific electroencephalographic 
patterns (interictal hypsarrhythmia and ictal voltage suppression). Adrenocorticotropic hormone 
(ACTH) was first employed to treat infantile spasms in 1958, and since then it has been tried 
in prospective and retrospective studies for infantile spasms. Oral corticosteroids were also 
used in a few studies for infantile spasms. Variable success in cessation of infantile spasms 
and normalization of electroencephalograms was demonstrated. However, frequent significant 
adverse effects are associated with ACTH and oral corticosteroids. Vigabatrin has been used 
since the 1990s, and shown to be successful in resolution of infantile spasms, especially for 
infantile spasms associated with tuberous sclerosis. It is associated with visual field constriction, 
which is often asymptomatic and requires perimetric visual field study to identify. When ACTH, 
oral corticosteroids, and vigabatrin fail to induce cessation of infantile spasms, other alternative 
treatments include valproic acid, nitrazepam, pyridoxine, topiramate, zonisamide, lamotrigine, 
levetiracetam, felbamate, ganaxolone, liposteroid, thyrotropin-releasing hormone, intravenous 
immunoglobulin and a ketogenic diet. Rarely, infantile spasms in association with biotinidase 
deficiency, phenylketonuria, and pyridoxine-dependent seizures are successfully treated with 
biotin, a low phenylalanine diet, and pyridoxine, respectively. For medically intractable infantile 
spasms, some properly selected patients may have complete cessation of infantile spasms with 
appropriate surgical treatments.
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Introduction
Infantile spasms are an age-specific epilepsy syndrome characterized by flexor, exten-
sor, and mixed flexor-extensor spasms which often occur in clusters and onset during 
first 2 years of life.1 Most of the infantile spasms are symptomatic and 9% to 15% 
of the cases were cryptogenic.2 West syndrome is diagnosed when infantile spasms, 
hypsarrhythmia and mental retardation are present.
Epidemiology
The incidence of infantile spasms is estimated at 0.20 to 0.60 per 100.3–8 The prevalence 
is 0.15 to 0.20/1000 children age 10 or younger.8,9
Clinical features and long-term outcome
The peak onset of infantile spasms is between 3 and 7 months, 93% before age 2 years; 
however, onset at birth and at 4.5 years has been reported.10 The spasms are bilateral Neuropsychiatric Disease and Treatment 2009:5 290
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sudden muscle contractions involving neck, trunk, and four 
extremities, and may be flexor, extensor, or mixed types. 
The spasms may be single, but often occur in clusters. The 
majority of the infantile spasms are symptomatic and may 
be associated with prenatal, perinatal, and postnatal causes, 
including brain dysgenesis; neurocutaneous syndromes such 
as tuberous sclerosis; metabolic disorders; chromosomal 
syndrome such as Down syndrome or gene abnormalities 
such as ARX gene mutations; hypoxic ischemic encepha-
lopathy; brain tumor; neonatal bacterial meningitis; and 
herpes simplex encephalitis, among others.1,10–12 Cryptogenic 
cases, characterized by lack of obvious evidence of brain 
damage or known etiology, comprise 9% to 15% of infantile 
spasms.2 The typical interictal electroencephalogram is 
hypsarrhythmia and classical ictal correlates may consist 
of fast wave bursts, high voltage slow waves, and general-
ized voltage attenuation or electrodecremental response.13,14 
About 10% to 25% of the patients with infantile spasms 
recover spontaneously.11,15,16 In the pre-adrenocorticotropic 
hormone (ACTH) era, long-term follow-up in 103 patients 
with infantile spasms, at age 5 years or older, showed that 
11% of children still had infantile spasms, 45% had other 
seizure types, and 55% were seizure-free; 13% over 1 year 
of age had normal intellectual capacity, and mortality was 
11% by age 2 years.17
In a prospective study of the outcome of 64 infants 
with infantile spasms treated during controlled studies 
of ACTH and prednisone, mean duration of follow-up 
was 50 months, and there was a 5% mortality rate in symp-
tomatic patients; 2 of 8 cryptogenic patients were cognitively 
normal, compared with 1 of the 56 symptomatic patients; 
infantile spasms persisted in 42% of children, whereas 53% 
of patients developed other seizure types and 47% were 
seizure-free; no difference in long-term intellectual outcome 
or epilepsy was associated with delay in treatment 5 weeks 
from onset of infantile spasms.18 However, in another 
prospective study of 102 infants with infantile spasms, with 
follow-up beyond 6 years, 50% of ACTH-treated patients 
were developmentally normal, 62% were seizure-free, 
and 39% had a normal EEG; better neurodevelopmental 
outcome was seen with early therapy of 1 month.19 Two 
other studies also revealed favorable long-term outcome of 
ACTH treatment within 1 month of onset for cryptogenic 
infantile spasms.20,21 Some studies reported equal efficacy 
of infantile spasms treatment in both symptomatic and cryp-
togenic groups,22 but other studies found a better response 
of treatment in the cryptogenic group.23,24 Additionally, the 
effect of hormonal therapy on long-term neurodevelopmental 
outcome is unclear, with some studies reporting a positive 
association between initial responsiveness to ACTH and 
improved long-term intellectual development,19,23,25 but 
other studies found no significant difference in prognosis 
between initial responders and nonresponders to hormonal 
therapy.18,26 Of patients with infantile spasms, 20% to 50% 
eventually evolve into Lennox-Gastaut syndrome.7,8,19,27 The 
patients with cryptogenic infantile spasms have 30% to 50% 
mental retardation compared with 80% to 95% for patients 
with symptomatic etiology.4,8,20,25–28
Treatment
The treatment of infantile spasms remains very challenging 
throughout the world. Over the years, the treatment choices 
have been surveyed and evaluated in the United States, Japan, 
the United Kingdom, and Europe.29–34 For example, in 1994, 
the survey report in the Child Neurology Society revealed 
ACTH as the first choice for the treatment of the infantile 
spasms, followed by valproic acid and oral corticosteroids as 
second and third choices, respectively.30 In another example, 
in 2000, a survey of the treatment of infantile spasms by the 
Japanese Epilepsy Society showed that vitamin B6 was the 
preferred first-line drug, followed by the combination of 
vitamin B6 and valproate or monotherapy with valproate; 
corticotropin was the third choice.31 Other surveys will be 
discussed later in the paper.
ACTH (adrenocorticotropic 
hormone)
Mechanism of ACTH and prednisone
ACTH may reduce neuronal excitability in infantile 
spasms by two mechanisms of action: (1) inducing steroid 
release and (2) a direct, steroid-independent action on 
melanocortin receptors. These combined effects may 
explain the robust, established clinical effects of ACTH in 
the therapy of infantile spasms.35 Additionally, suppression 
of corticotropin-releasing hormone (CRH), an excitant 
neuropeptide, by ACTH/steroids was proposed as another 
mechanism for ACTH treatment of infantile spasms.36 
However, there is considerable debate about the reasons 
why ACTH and prednisone are useful in infantile spasms, 
their mechanism of action, and their long-term effects on 
brain development.37
The therapeutic effect of ACTH in infantile spasms 
was initially reported in a series of children with infantile 
spasms and hypsarrhythmia.38 Since then, both prospective 
and retrospective studies with ACTH have been conducted 
for the treatment of infantile spasms.Neuropsychiatric Disease and Treatment 2009:5 291
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In one prospective study, 26 patients receiving the high-dose 
therapy were treated as follows: 150 U/m2/day for 3 weeks, 
80 U/m2/day for 2 weeks, 80 U/m2 every other day for 
3 weeks, and 50 U/m2/day every other day for 1 week, with 
the dosage then tapered to zero during a 3-week period; the 
24 patients assigned to the low-dose therapy group received 
20 to 30 U/day for 2 to 6 weeks; the dosage was then 
tapered to zero during a 1-week period.39 The response was 
defined as cessation of infantile spasms and disappearance 
of hypsarrhythmia. Among 26 patients treated with the 
high-dose therapy, 13 (50%) responded; of the 24 patients 
treated with the low-dose therapy, 14 (58%) responded. No 
significant difference in the cessation of infantile spasms 
and improvement of the electroencephalogram was demon-
strated in the two groups. Additionally, no difference in the 
relapse rate between the two groups was noted. Furthermore, 
the side effects seen in both treatment groups were similar, 
except that hypertension occurred more frequently in the 
high-dose group. In another report, there is no evidence that 
high-dose ACTH treatment (150 U/m2/day) is more effective 
than low-dose ACTH (20–30 U/day).23 The relapses of 
the infantile spasms often occur in one third to one half of 
patients, and a second course of ACTH is often effective.22 In 
another prospective randomized controlled study, low-dose 
ACTH (0.005 mg/kg/day = 0.2 IU/kg/day) or high-dose 
(0.025 mg/kg/day = 1 IU/kg/day) synthetic ACTH therapy 
showed no difference in the initial and long-term seizure 
and developmental outcomes in the 17 responders who were 
followed up for longer than 1 year after the completion of 
ACTH therapy.40 The optimal dose of ACTH is still unknown 
based on the above studies.
In the report of the American Academy of Neurology 
and the Child Neurology Society on the medical treatment of 
infantile spasms, 14 studies on ACTH including 5 randomized 
controlled studies, 4 prospective, open-label trials, and 
5 retrospective studies were reported.11 ACTH dosage ranged 
from 0.2 IU/kg to 150 IU/m2, the duration of treatment was 
from 4 to 12 weeks, the rate of cessation of infantile spasms 
was from 42% to 87%, time from initial treatment to cessation 
of infantile spasms was from 7 to 12 days, and the relapse rate 
of infantile spasms varied from 15% to 33%.11
Oral corticosteroids
Five studies including 2 randomized controlled studies, 
2 prospective open-label studies and 1 retrospective study 
with 2 to 3 mg/kg prednisone or prednisolone from 2 to 
32 weeks.11 The cessation rate of infantile spasms varied 
from 29% to 59%.
ACTH versus oral corticosteroids
A prospective randomized single-blinded study with 2-week 
ACTH 150 IU/m2 was compared with 2-week oral prednisone 
2 mg/kg, revealing superior efficacy of high-dose ACTH 
in the cessation of infantile spasms and disappearance of 
hypsarrhythmia.41 Of 15 infants randomized to ACTH, 13 
responded by EEG and clinical criteria (86.6%); 4 of the 14 
patients given prednisone responded (28.6%). A double-
blind, placebo-controlled, crossover study to compare the 
therapeutic effectiveness of ACTH (20 to 30 units/day) with 
that of prednisone (2 mg/kg/day) showed no difference in the 
cessation of infantile spasms and disappearance of hypsar-
rhythmia between ACTH and prednisone.22 High-dose ACTH 
150 IU/m2 was superior to prednisone 3 mg/kg in the cessa-
tion of infantile spasms with 100% in ACTH versus 59% in 
prednisone, 97% disappearance of hypsarrhythmia in ACTH 
versus 50% in prednisone.24 However, some patients who do 
not initially respond to ACTH may respond to prednisone 
and vice versa.22
Side effects of ACTH and oral 
corticosteroids
Hypertension 0% to 37% (4 studies), irritability 37% to 
100% (3 studies), infection 14% (1 study), cerebral atrophy 
62% (1 study), 5 deaths in 304 cases (2 were associated 
with sepsis attributed to ACTH) were seen in randomized 
controlled studies.11
Vigabatrin
Vigabatrin, a structural analogue of gamma-aminobutyric 
acid (GABA), is an irreversible inhibitor of GABA trans-
aminase and increases the GABA levels, an inhibitory 
neurotransmitter, in the brain.42 In a randomized, placebo-
controlled study of vigabatrin as first-line treatment of 
infantile spasms, compared with baseline, the patients treated 
with vigabatrin had a 78% reduction in infantile spasms 
compared with 26% in the group treated with placebo, at 
the end of the double-blind phase.29 In a randomized trial of 
vigabatrin in patients with infantile spasms, resolution rate 
of infantile spasms was 23% at 2 weeks after treatment, and 
65% at the end of a 3-month open-label period; the efficacy 
and safety of vigabatrin in patients with infantile spasms, 
particularly among those with infantile spasms secondary to 
tuberous sclerosis, was demonstrated.43 In other open-label 
uncontrolled prospective studies, the response rate was better 
in cryptogenic infantile spasms (50% to 100%) compared 
with the symptomatic cases (0% to 59%), the time from 
initiation of therapy to cessation of infantile spasms varied Neuropsychiatric Disease and Treatment 2009:5 292
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from 12 to 35 days, and the vigabatrin dosages ranged from 
18 to 200 mg/kg/day.11 Additionally, the treatment response 
of infantile spasms to vigabatrin in the infants with tuberous 
sclerosis was uniformly favorable, with cessation of infantile 
spasms varying from 91% to 100%.43–49
Vigabatrin 100 to 150 mg/kg/day was compared with 
ACTH in the treatment of infantile spasms and the resolution 
rate of infantile spasms was similar for both vigabatrin and 
ACTH; however, the improvement of hypsarrhythmia was 
better for ACTH.48,50 In the United Kingdom, ACTH treat-
ment induced complete cessation of infantile spasms better 
than vigabatrin initially, but not at 12 to 14 months of age; 
better initial cessation of infantile spasms by ACTH treatment 
in those with no identified underlying etiology may lead to 
improved developmental outcome.51
Side effects of vigabatrin
In both randomized controlled studies and open-label 
uncontrolled studies, sedation, irritability, insomnia and 
hypotonia were reported in vigabatrin treatment.11 Concentric 
visual field defects and abnormalities in electroretinograms 
were also demonstrated in children; however, the incidence 
in infants under 1 year of age is unknown currently.11,52–54
Valproic acid
Valproic acid enhances GABA-ergic inhibitory system at 
the cortical and subcortical levels and blocks neuronal firing 
by blocking voltage-gated sodium channels.42 In an uncon-
trolled, open-label, prospective study, cessation of infantile 
spasms in 73% and resolution of hypsarrhythmia in 91% 
of 22 patients (18 with symptomatic infantile spasms and 
4 with cryptogenic infantile spasms) were reported after 6 
months of therapy with valproic acid 40 and 100 mg/kg/day.55 
However, relapse of infantile spasms in 23% of patients was 
seen in the first 7 months of treatment. In another open-label, 
uncontrolled, prospective study, cessation of infantile spasms 
was seen in 72% of the patients with infantile spasms after 
3 months of treatment with valproic acid.56
Common side effects of valproic acid include weight gain, 
nausea, vomiting, hair loss, easy bruising, tremor; rare idio-
syncratic effects consist of agranulocytosis, Stevens–Johnson 
syndrome, aplastic anemia, hepatic failure, dermatitis–rash, 
serum sickness, and pancreatitis.42,57
Nitrazepam
Mechanism of nitrazepam in the treatment of infantile spasms 
may be related to their effect in modification of the sensitiv-
ity of GABA receptors.58 In the retrospective case series, 
nitrazepam 0.5 to 3.5 mg/kg/day was reported to induce reso-
lution of infantile spasms from 30% to 54% and disappearance 
of hypsarrhythmia from 15% to 46%.59,60 Another prospective 
randomized multicenter study comparing corticotropin with 
nitrazepam revealed no difference in efficacy in the treatment 
of infantile spasms.61
Nitrazepam was associated with excess sedation, 
hypersalivation, swallowing difficulty, high incidence of 
aspiration pneumonia, and several deaths.62,63
Pyridoxine
Pyridoxine is a coenzyme of glutamic acid decarboxylase 
and enhances GABA synthesis.64 Low levels of GABA in 
cerebrospinal fluid of infants with infantile spasms were 
reported.65 Pyridoxine is the first treatment of choice for 
infantile spasms in Japan.31,32,66 Two uncontrolled prospec-
tive open-label studies in infantile spasms revealed efficacy 
for infantile spasms.67,68 At dosages of pyridoxine 1 g/day 
(usual dose of pyridoxine 10 to 50 mg/kg/day), a complete 
control of infantile spasms was reported in 35% to 40% of 
cryptogenic cases but only 10% of symptomatic cases.67 
Side effects of high-dose pyridoxine include loss of appetite, 
irritability and vomiting. 68
Pyridoxine-dependent seizures are characterized by 
intractable seizures including infantile spasms that are not 
controlled with anticonvulsants but that respond both clini-
cally and electrographically to 100 tp 500 mg of intravenous 
pyridoxine.69 Pyridoxine-dependent seizures, an autosomal 
recessive disorder, is caused by mutations in the ALDH7A1 
gene on chromosome 5q31.69 The patients require lifetime 
treatment with pyridoxine at 15 to 20 mg/kg/day.69
Zonisamide
Zonisamide blocks repetitive firing of voltage-sensitive 
sodium channels, reduces voltage-sensitive T-type calcium 
currents without affecting L-type calcium currents, and is a 
weak carbonic anhydrase inhibitor.70 In one add-on nonblind 
study, zonisamide 4 to 20 mg/kg/day in 27 children with 
infantile spasms (25 symptomatic and 3 cryptogenic cases) 
induced cessation of infantile spasms and resolution of 
hypsarrhythmia in 33%; however, a 50% recurrence rate was 
also reported.71 In another add-on nonblind study, 16 patients 
with infantile spasms (13 symptomatic and 3 cryptogenic 
cases) were treated with 4 to 8 mg/kg/day zonisamide after 
failing to respond to pyridoxine and valproic acid. Only 
2 patients showed cessation of infantile spasms but no 
recurrence of infantile spasms after 26 months of follow-up.72 
Zonisamide monotherapy 3 to 10 mg/kg/day was administered Neuropsychiatric Disease and Treatment 2009:5 293
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in 11 patients with newly diagnosed infantile spasms 
(cryptogenic 3, symptomatic 8) as the second-choice drug 
that failed to respond to high-dose vitamin B6. The cessation 
of infantile spasms and disappearance of the hypsarrhythmia 
in 4 symptomatic patients (36%) were achieved after 1 to 
5 days of treatment, however there were two relapses (50%) 
4 to 6 weeks after cessation of seizures.73 In another study, 
the long-term effectiveness of zonisamide was evaluated in 
11 patients with West syndrome (7 symptomatic) who had 
cessation of spasms with zonisamide monotherapy. During 
the follow-up period (24 to 79 months), this response was 
maintained in 7 patients (relapse rate = 36%).74 Recently, 
6 of 23 (26%) patients with symptomatic infantile spasms 
became spasm-free on zonisamide.75
Common side effects of zonisamide in children include 
anorexia, dizziness, ataxia, fatigue, somnolence, and confu-
sion; rare idiosyncratic effects consist of nephrolithiasis, 
oligohydrosis, and hyperthermia.57
Topiramate
Topiramate blocks voltage-sensitive sodium channels, 
enhances the activity of GABA, an inhibitory neurotransmit-
ter, blocks the action of glutamate, an excitatory neurotrans-
mitter, and is also a weak carbonic anhydrase inhibitor.42,76 In 
a nonblind add-on pilot study with topiramate 25 mg daily 
up to 24 mg/kg/day on 11 children with refractory infantile 
spasms, 5 (45%) became spasm-free during the study, with 
absence of infantile spasms and hypsarrhythmia.77 Eleven 
children with infantile spasms who completed the pilot study 
entered an 18-month study in which the dosages of topiramate 
and other anticonvulsants were adjusted to optimal response 
(maximum, 50 mg/kg/day). Four (50%) children were spasm-
free, 7 (88%) had experienced a 50% reduction in spasms, 
and 3 (38%) were able to achieve topiramate monotherapy.78 
Topiramate was well tolerated in that no patients discontinued 
because of adverse events. In a prospective, 2-month study 
with topiramate 3 to 27 mg/kg/day in 15 children with 
recently diagnosed infantile spasms, 3 patients became 
spasm-free (20%), 5 had 50% reduction, 3 had at least 25% 
reduction, 4 patients did not respond, and 3 of 15 patients 
had cessation of hypsarrhythmia.79 Topiramate treatment in 
children with West syndrome was reported in a retrospective 
multicenter evaluation of 100 patients: 17.5% of patients 
became free of seizures, and in 47%, the seizure frequency 
decreased by at least 50%; additionally, hypsarrhythmia 
remitted in 18 of 83 cases.80
Common side effects of topiramate include anorexia, 
weight loss, word-finding disturbance, cognitive slowing, 
ataxia, poor concentration, dizziness, fatigue, paresthesia, 
somnolence; rare side effects consist of nephrolithiasis, 
hypohidrosis, acute angle closure glaucoma.42,57
Felbamate
Felbamate potentiates GABA-mediated inhibition, blocks 
voltage-dependent sodium channels, and the ionic channel at 
the N-methyl-d-aspartate receptor.42 In one nonblind add-on 
study, felbamate 15 to 45 mg/kg/day resulted in cessation 
of infantile spasms in 3 of 4 patients, all refractory to 
conventional antiepileptic drugs.81 In another nonblind study 
for refractory infantile spasms, in which 4 of 6 patients were 
refractory to both corticosteroids and new antiepileptic drugs 
(vigabatrin and lamotrigine), felbamate 15 to 45 mg/kg/day 
treatment decreased seizure frequency by 75%.82
Felbamate common side effects consist of nausea, 
vomiting, anorexia, weight loss, insomnia, dizziness, 
headache and ataxia; rare serious idiosyncratic effects include 
aplastic anemia, and hepatic failure.42,57
Lamotrigine
Lamotrigine has been shown to act at voltage-sensitive 
sodium channels, stabilizing neural membranes and inhibit-
ing the release of excitatory neural transmitters.42 The dosage 
of lamotrigine can be titrated slowly up to 5 mg/kg/day when 
combined with valproate, but can be gradually increased 
to 15 mg/kg/day when not combined with valproate. In a 
single-blind, placebo-controlled, add-on study, 30 patients 
with infantile spasms refractory to conventional antiepileptic 
drugs and to vigabatrin and corticotropin were treated with 
lamotrigine, 9 patients showing 50% decrease in infantile 
spasms, 5 of these with complete cessation of spasms.83 
Three infants affected with symptomatic West syndrome, 
unresponsive to vigabatrin and to ACTH, were successfully 
treated with very small doses of lamotrigine.84 Common 
side effects of lamotrigine include rash, nausea, dizziness, 
and somnolence; rare idiosyncratic effects include Stevens–
Johnson syndrome and hypersensitivity syndrome.42,57
Levetiracetam
Levetiracetam binds to synaptic vesicle protein, has actions 
on neuronal GABA- and glycine-gated currents, as well as 
voltage-dependent potassium currents, however, its exact 
mechanism of action is unknown.57 In an open-label add-
on study of levetiracetam 10 to 60 mg/kg/day in refractory 
childhood epilepsy syndromes, efficacy was demonstrated 
in one patient’s infantile spasms.85 Refractory infantile 
spasms in another infant were responsive to levetiracetam Neuropsychiatric Disease and Treatment 2009:5 294
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15 mg/kg/day, resulting in cessation of infantile spasms for 
6 months.86 Treatment with levetiracetam 30 mg/kg/day for 
cryptogenic West syndrome resulted in cessation of infantile 
spasms in 2 patients, a 50% reduction in seizure frequency 
in 2 patients, but no improvement in seizure frequency in 
another patient. There were no relapses in the two patients 
at 6 months after the cessation of seizures.87
Common side effects of levetiracetam include somnolence, 
headache, anorexia, and nervousness. Less frequent 
side effects consist of agitation, aggression, anxiety, or 
depression.57
Thyrotropin-releasing hormone
A daily dose of thyrotropin-releasing hormone 0.5 to 1 mg 
was administered intravenously or intramuscularly for 1 to 
4 weeks. The follow-up periods were 3 to 12 months (mean 
6 months). Complete cessation of spasms was achieved in 
7 of 13 (53.7%) of those with infantile spasms, and marked 
improvement of electroencephalograms was observed in 
8 of 13 (61.5%) of these.88 Thyrotropin-releasing hormone 
was shown to increase cerebrospinal fluid kynurenine 
level.89 Thyrotropin-releasing hormone may act as an anti-
epileptic through a kynurenine mechanism, considering 
that kynurenic acid acts as an antagonist on the N-methyl-
D-aspartate receptor complex.90 Additionally, thyrotropin-
releasing hormone-mediated increase in GABA release 
has also been demonstrated and may contribute to its 
anti-epileptic effects.91 The effectiveness of thyrotropin-
releasing hormone was also reported in West syndrome, 
Lennox-Gastaut syndrome, and early infantile epileptic 
encephalopathy that were intractable to anticonvulsants and 
adrenocorticotrophic hormone.90,92
Ganaxolone
Ganaxolone is an allosteric modulator of GABA receptors 
acting through binding sites, which are distinct from the 
benzodiazepine binding site.93,94 In a multicenter, open-
label, add-on trial, investigating the safety and efficacy of 
ganaxolone up to 36 mg/kg/day in children with refractory 
infantile spasms, infantile spasm frequency was reduced by 
at least 50% in 33% of these subjects, with an additional 
33% experiencing some improvement (25% to 50% reduc-
tion in spasm frequency); ganaxolone was well tolerated, 
and adverse events attributed to ganaxolone were generally 
mild, consisting of somnolence, diarrhea, nervousness, and 
vomiting.95 In another add-on nonblind study, ganaxolone 
treatment in 20 children with infantile spasms refractory to 
corticosteroids, lamotrigine and vigabatrin, only 1 patient had 
cessation of infantile spasms and 50% decrease in seizure 
frequency in 50% of the patients.58
Liposteroid
Dexamethasone palmitate (liposteroid) was used for the 
treatment of West syndrome and compared with adrenocor-
ticotropic hormone (ACTH) therapy.96 A single intravenous 
injection of liposteroid (0.25 mg/kg) was administered 
seven times in 3 months (total dosage = 1.75 mg/kg) to 
5 symptomatic patients with West syndrome, aged 4 to 
11 months. ACTH (0.025 mg/kg/day) was administered 
intramuscularly for 6 weeks (total dosage = 0.625 mg/kg) 
to 5 symptomatic patients with West syndrome, aged 6 to 
10 months. Infantile spasms and hypsarrhythmia on EEG 
disappeared in all 5 patients in the liposteroid therapy group 
within 4 doses; in the ACTH therapy group, infantile spasms 
and hypsarrhythmia on EEG similarly disappeared during 
treatment in all 5 patients, but infantile spasms reappeared 
2 months after therapy in 2 patients. No notable adverse 
reactions occurred in the liposteroid group, but transient 
dysfunction of the thyroid and anterior pituitary gland and 
increased levels of serum cortisol were experienced in the 
ACTH group.96 In another study, a single intravenous injec-
tion of liposteroid (0.25 mg/kg) was administered 12 times 
in 1 month (total dosage 3.0 mg/kg) to 4 patients with West 
syndrome. All 4 patients previously had daily seizures uncon-
trolled by conventional antiepileptic drugs, such as valproic 
acid, clonazapam or zonisamide. Infantile spasms and hypsar-
rhythmia on EEG disappeared in 1 patient within 4 doses; a 
greater than 50% decrease in seizures, and EEG improvement, 
were found in another 2 patients; no notable effects were seen 
in the other 2 patients. There were no clinically significant 
adverse reactions throughout the therapy.97
Sulthiame
Sulthiame is a carbonic anhydrase inhibitor that is widely 
used to treat partial and myoclonic seizures. Sulthiame 
(5 to 10 mg/kg/day) was studied in a randomized double-
blind placebo-controlled add-on trial on baseline pyridoxine 
medication for the primary therapy of West syndrome and 
was found to have a positive effect in the primary therapy of 
West syndrome. Based on the intention to treat, 6 (30%) of 
20 patients responded to sulthiame, reaching complete ces-
sation of infantile spasms and resolution of hypsarrhythmia, 
while no patients on placebo responded (p  0.025).98 Side 
effects of sulthiame occurred in 48% of patients, including 
vomiting in 38%, somnolence in 20%, restlessness in 16%, 
loss of appetite in 5.5%, and diarrhea in 3%.98Neuropsychiatric Disease and Treatment 2009:5 295
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Intravenous immunoglobulin (IVIg)
In one study, 6 children with cryptogenic infantile spasms 
and 5 with symptomatic infantile spasms were treated with 
IVIg at 100 to 200 mg/kg of body weight at intervals of 
2 or 3 weeks (6 to 10 administrations). All 6 patients with 
cryptogenic West syndrome showed complete remission 
in accordance with normalized electroencephalogram. 
Of the 5 patients with symptomatic West syndrome, 1 
showed cessation of clinical spasms in agreement with EEG 
improvement and 2 others revealed transient cessation of 
spasms with recurrence.99 Five of 23 patients with infantile 
spasms experienced cessation of infantile spasms with 
1 g/kg of IVIg for 2 days, repeated every 3 weeks for 6 
months.100
Ketogenic diet
Since the early 1920s, the ketogenic diet has been used 
successfully to treat patients with intractable epilepsy; 
however, the mechanism by which the diet protects against 
seizures is unknown. The ketogenic diet is a calorie-restricted 
diet in which the fat:carbohydrate plus protein ratio ranges 
from 2:1 to 5:1. During a 4-year period, 23 children with 
infantile spasms, aged 5 months to 2 years, were started on 
the ketogenic diet; at 3, 6, 9, and 12 months, 38%, 39%, 53%, 
and 46%, respectively, of all patients currently on the diet 
were  90% improved (3 were seizure-free at 12 months); 
67%, 72%, 93%, and 100% were 50% improved.101 In 
another retrospective study, the ketogenic diet achieved 
the spasm-free state in 53.5% (23/43) of patients and a 
greater than 90% reduction of spasms in 62.8% (27/43) of 
patients; the spasm outcomes were highly concordant with 
improvements in EEG findings and development.102 In a 
retrospective study, a case-control evaluation was performed 
for the ketogenic diet versus ACTH for new-onset infantile 
spasms, including 13 patients on the ketogenic diet and 20 
patients on high-dose ACTH. Eight of 13 (62%) infants 
treated with the ketogenic diet were spasm-free within 1 
month, compared with 18 of 20 (90%) treated initially with 
ACTH; ACTH-treated infants were more likely to have a 
normal EEG at 1 month; side effects (31% vs 80%, p = 0.006) 
and relapse rate after initial success (12.5% vs 33%, p = 0.23) 
were lower with the ketogenic diet.103
Early side effects in the initial 4 weeks of treatment may 
consist of transient dehydration, nausea, vomiting, diarrhea, 
constipation, lethargy, hypoglycemia, hypercholesterolemia, 
hypertriglyceridemia, hyperuricemia, hypoproteinemia, 
hypomagnesemia, hyponatremia, low concentrations of 
high-density lipoprotein, hepatitis, acute pancreatitis, 
metabolic acidosis, hemolytic anemia, and Fanconi renal 
tubular acidosis; later side effects include osteopenia, renal 
stones, cardiomyopathy, secondary hypocarnitinemia, and 
iron-deficiency anemia.104–106
Combination therapies
Nine infants with an underlying static encephalopathy 
and newly diagnosed infantile spasms were treated in 
an open study with ACTH and vigabatrin. The ACTH 
was discontinued after 4 to 6 weeks and the infants were 
maintained on vigabatrin alone. Following an initial response 
with complete cessation of infantile spasms in all 9 patients, 
a long-term spasm cessation for a mean of 19.2 months was 
reported in all but one child.107 Ninety-four patients with 
West syndrome were treated with sodium valproate and 
steroids, starting with hydrocortisone orally for 2 weeks. If 
spasms stopped, hydrocortisone was withdrawn, if spasms 
persisted, tetracosactrin (synthetic ACTH) was administered 
for another 2 weeks, and then hydrocortisone was slowly 
withdrawn. Spasms cessation was 72% for cryptogenic 
and 60% for symptomatic infantile spasms at 31-month 
follow-up.108 In 4 patients with cryptogenic and 1 patient 
with symptomatic (tuberous sclerosis) West syndrome, the 
combined therapy with topiramate and vigabatrin achieved 
a rapid and complete cessation of infantile spasms, and in 
3 patients with cryptogenic West syndrome, the EEG also 
became normal.109
Rare treatable symptomatic 
infantile spasms
Rarely, infantile spasms occur in association with 
biotinidase deficiency, which can be treated with biotin 
successfully.110 Children with infantile spasms associated 
with phenylketonuria have been reported and were treated 
successfully with low phenylalanine diet and valproic 
acid or nitrazepam.111
Surgical treatment
In 4 infants with cryptogenic infantile spasms, positron emis-
sion tomography effectively identified unsuspected focal 
cortical dysplasia and all 4 patients were spasm-free after 
resective surgery.112 In another study, 23 infants and children 
underwent cortical resection (n = 15) or hemispherectomy 
(n = 8) for intractable infantile spasms; convergence between 
electroencephalogram and neuroimaging localization was a 
prerequisite to surgery; at follow-up (range 4 to 67 months; 
mean 28.3 months), 15 children were spasm-free, 3 had 90% 
spasm reduction, 1 had 75% spasm reduction, and 4 failed Neuropsychiatric Disease and Treatment 2009:5 296
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to benefit from surgery in terms of seizure frequency.113 
Twenty-four children receiving resection surgery for 
medically intractable infantile spasms showed a significant 
increase in developmental level at 2 years post surgery 
compared with presurgical levels.114 A favorable outcome of 
multiple sub-pial transection in 2 patients who had intractable 
atypical infantile spasms preceded by partial seizures, without 
any lateralized magnetic resonance imaging abnormalities, 
was recently reported.115 Infantile spasms associated with 
cortical dysplasia requiring treatment with lesionectomy 
in the right perirolandic area at 49 weeks conceptional age 
in one infant and left temporo-occipital disconnection at 
45 weeks in the other infant, resulted in Engel classification 
I and catch-up developmental progress.116 For patients 
without a surgically resectable lesion, corpus callosotomy 
has been reported to improve dramatically infantile spasms, 
as well as other seizure types, such as drop attacks.117 After 
complete callosotomy, infantile spasms disappeared in 
80% of 17 cases; drop attacks were dramatically reduced or 
completely stopped in 90% of the children. However, the 
excellent response of callosotomy in infantile spasms would 
require more studies for confirmation.
Conclusion
According to a 2008 Cochrane review,122 hormonal treatment 
resolves infantile spasms in more infants than vigabatrin, but 
this may or may not translate into a better long-term outcome. 
If prednisone or vigabatrin are used, then high dosage is 
recommended. Vigabatrin may be the treatment of choice 
for infantile spasms associated with tuberous sclerosis. In the 
United States of America, ACTH is probably an effective 
agent in the short-term treatment of infantile spasms and 
vigabatrin is possibly effective as suggested by the practice 
parameter: medical treatment of infantile spasms: report 
of the American Academy of Neurology and the Child 
Neurology Society.11 In Japan, the most recent survey in 
2006 on treatment of infantile spasms reveals vitamin B6 as 
the first-choice drug, followed by valproic acid, zonisamide, 
and adrenocorticotropic hormone; however, in cryptogenic 
patients, ACTH was used most frequently, usually within 
1 month after disease onset, followed by valproic acid, 
vitamin B6, and zonisamide.32 The 2004 National Institute for 
Clinical Excellence (NICE) Guidelines,118 the 2005 Scottish 
Intercollegiate Guidelines Network (SIGN) Guidelines,119 
and the 2005 US Pediatric Epilepsy survey 33 all support the 
use of vigabatrin as first-line therapy for infantile spasms 
associated with tuberous sclerosis complex. However, 
only the NICE Guidelines support vigabatrin as the drug of 
choice in symptomatic infantile spasms. In a recent survey 
in the United Kingdom, hormone treatment controlled 
infantile spasms better than vigabatrin initially, but not at 
12 to 14 months of age. Better initial control of infantile 
spasms by hormone treatment in those with no identified 
underlying etiology may lead to improved developmental 
outcome.51 In another recent survey, vigabatrin is the first 
choice for infantile spasms associated with tuberous sclerosis 
or symptomatic etiologies; ACTH and prednisone also are 
as good as other first-line options.34
When children fail to have complete cessation of infantile 
spasms after treatment with ACTH, vigabatrin, or prednisone, 
some other medications have been used to treat infantile 
spasms with variable success in cessation of infantile spasms. 
In uncontrolled studies, these include topiramate, zonisamide, 
valproic acid, nitrazepam, lamotrigine, levetiracetam, 
felbamate, high-dose pyridoxine, liposteroid, ganaxolone, 
and thyrotropin-releasing hormone. Other alternative 
treatment for infantile spasms may consist of intravenous 
immunoglobulin and a ketogenic diet. Some selective 
children with medically intractable infantile spasms may 
have excellent success in resolution of spasms with proper 
surgical treatment options.
More research is necessary on the pathophysiology 
of infantile spasms, such as that conducted for recent 
animal models of infantile spasms,120 so that we can treat 
infantile spasms more successfully. Finally, infants with 
West syndrome could be identified several weeks before 
the occurrence of hypsarrhythmia by a typical EEG 
pattern, which may open the way for early intervention 
to prevent development of hypsarrhythmia and infantile 
spasms.121
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